Clinical Trial: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Type 2 Diabetes Mellitus
Study Type: INTERVENTIONAL
Official Title: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg
Brief Summary:
The study will look at how well CagriSema helps people lower their blood sugar and body weight.CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide.CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone.CagriSema will also be compared to a "dummy" medicine without any active ingredient.The study will be done in participants who have type 2 diabetes.Participants will take the study medicine together with the…
Read more